<p>Toni Choueiri discusses the updated data from different cohorts of this novel HIF inhibitor.</p>

Toni Choueiri discusses the updated data from different cohorts of this novel HIF inhibitor.

Episode 392: ASCO GU 2025 - HIF Inhibition with Casdatifan in Refractory RCC

Broadcasting the latest developments in GU cancer

Hosted by Brian Rini and Tom Powles 

Brian Rini MD is a Professor of Cancer Research and Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center
Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London

Medicine

Health & Fitness

Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is a Professor of Cancer Research and Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London

Share Episode 392: ASCO GU 2025 - HIF Inhibition with Casdatifan in Refractory RCC

Sign up to save your podcasts

Episode 392: ASCO GU 2025 - HIF Inhibition with Casdatifan in Refractory RCC

Episode 392: ASCO GU 2025 - HIF Inhibition with Casdatifan in Refractory RCC

More shows like The Uromigos

JAMA Editors' Summary

Prostate Cancer Update

NEJM This Week

JAMA Clinical Reviews

AFP: American Family Physician Podcast

ASCO Daily News

White Coat Investor Podcast

The Curbsiders Internal Medicine Podcast

The Peter Attia Drive

Annals On Call Podcast

The Clinical Problem Solvers

GU Cast | Urology Podcast

BioCentury This Week

Two Onc Docs

The View on GU | with Lalani and Wallis